Specjalistyczny Szpital Onkologiczny Nu-Med Sp. z o.o.
- Address
- lock Available on a paid plan
Specjalistyczny Szpital Onkologiczny Nu-Med Sp. z o.o.
Specjalistyczny Szpital Onkologiczny Nu-Med is a comprehensive oncology research center specializing in advanced Phase II and Phase III clinical trials across multiple cancer types. The center demonstrates particular expertise in evaluating novel targeted therapies, immunotherapies, and antibody-drug conjugates for both solid tumors and hematologic malignancies.
- Breast cancer research including HER2-positive, hormone receptor-positive, triple-negative, and metastatic breast cancer with emerging targeted agents and combination therapies
- Gastrointestinal malignancies encompassing colorectal cancer, biliary tract cancer, and gastric/GEJ/esophageal cancers with focus on personalized medicine approaches
- Thoracic oncology trials in non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) utilizing immunotherapy combinations and chemoradiation strategies
- Head and neck cancers, melanoma, and hematologic malignancies including peripheral T-cell lymphoma with novel immunomodulatory agents
The facility's research portfolio emphasizes precision oncology with biomarker-driven trials, including studies targeting ESR1 mutations, HER2 expression, PD-L1 status, and microsatellite stability. Nu-Med actively investigates post-surgical adjuvant therapies, neoadjuvant treatment strategies, and advanced-stage disease management, contributing to the development of next-generation cancer therapeutics across the entire disease continuum from early-stage to metastatic settings.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 of 2 therapeutic areas and 15 of 68 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 67 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AstraZeneca AB2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB11trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Specjalistyczny Szpital Onkologiczny Nu-Med Sp. z o.o.
lock Showing 1 of 22 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study Comparing Sigvotatug Vedotin and Docetaxel in Adults with Previously Treated Non-Small Cell Lung Cancer | Seagen Inc. | Phase III | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 68 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Capecitabine | 7 | Unknown | 2019-04-15 | 2026-05-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.